Screening for left ventricular dysfunction may have less value than thought

The value and cost-effectiveness of screening for left ventricular (LV) dysfunction remains unclear, particularly since specific, evidence-based treatments are not available for the majority of patients with preserved systolic dysfunction, reports a study in the June issue of the Journal of Cardiac Failure.

Read the whole article on Physorg

More from Physorg